HUE028512T2 - Géntranszfer légúti epiteliális õssejtbe, RNS-vírus tüskefehérjével pszeudotipizált lentivírusvektor alkalmazásával - Google Patents

Géntranszfer légúti epiteliális õssejtbe, RNS-vírus tüskefehérjével pszeudotipizált lentivírusvektor alkalmazásával Download PDF

Info

Publication number
HUE028512T2
HUE028512T2 HUE06822478A HUE06822478A HUE028512T2 HU E028512 T2 HUE028512 T2 HU E028512T2 HU E06822478 A HUE06822478 A HU E06822478A HU E06822478 A HUE06822478 A HU E06822478A HU E028512 T2 HUE028512 T2 HU E028512T2
Authority
HU
Hungary
Prior art keywords
vector
virus
gene
vectors
cells
Prior art date
Application number
HUE06822478A
Other languages
English (en)
Inventor
Katsuyuki C/O Id Pharma Co Ltd Mitomo
Makoto C/O Id Pharma Co Ltd Inoue
Hitoshi C/O Id Pharma Co Ltd Iwasaki
Mamoru C/O Id Pharma Co Ltd Hasegawa
Eric W Alton
Uta Griesenbach
Original Assignee
Id Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Pharma Co Ltd filed Critical Id Pharma Co Ltd
Publication of HUE028512T2 publication Critical patent/HUE028512T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (5)

  1. Szabsdatmt igénypontok í. Rekonthináns SlV-vektnr «isstáá itbrázis: \0®®ji$ßm történő aifc#sazásra, mêây kópiás őgf:^l olyas légúti eplteliáiis őssejtbe joitaíááa pso történik, ssSeípt nem vetettek alá előkezelésnek- vagy eÄesädb emnáló kezelésnek, ahol a vektor (u a Smsdii viras f és HN burokpikeprotemjei tu$keiehésjèlve| teifFl pszesnkaipi&itvs w, ès (H) kleges g#i tatîaknaz expmssxáihátő állapotban, valamint aboi s vektor Msn tövé teszi ax idegen gén beépülését stz őssejtbe, miáltal biztosítja m IbeiM gén ppíább 5Ő0 nsptg t«#* hsmuMàvh expresxziéját,
  2. '2. Rekornbmáns SlV-vektnr alkaimatá^-ásztás fibrèzis kezelésére szolgéiő igyógyszsr ejiáipsábp, almi; (a) a vektor a Sendai virus F és ΗΉ bstrek-gllkoprotemjei tliskefehérjéivei pszetKktíipizálvti vart # idegen gént tartalmaz espresszálhaté állapotban, valamint a vektor lehetővé tes*! az idegen gén beephléset légntí epkeilális őssejtbe, miáltal biztosítja az Idegen gén legalább 3őÖ napig t&rto, hosszaiévá expresszióját, és (b) a gyógyszer légéi t epiteüális őssejteknek történd beadásra szolgák
  3. 3. Az L igénypont szerinti vektor vagy a 2. igénypont szerinti alkalmazás, aboi a rekombmáns Si¥-vektor agm törzsből származik.
  4. 4. A 1· igénypont szerinti vektor vagy aSkainrazás,..ahol a rekombináns SlV-vektor önmagát inaktiváló vektor, ahol a 3' LTR U3 régió protnótor-^zékvenelá|a elióináiva van éslvagy másik preanóser-szekveneiáva! van helyettesítve.
  5. 5. Az b. 3- vagy·' 4, igénypont szkinti vektor skp' áf-d. igénypontok bármelyike szerinti alkalmasáé, ahol az idegen gén a következők bármelyikét kódold gén: (a) mherens vagy szerzett, tbszfitnkeionáiis clsztás bbrósist (CF) okozó Mtor, (b) inherots vagy szerzett, disziuekdonils CFTR-léMrje, (c) fehérje, amelynek terápiás hatása van «tisztás űbrőzlsfean, (d) CFTRdehéde, snmly szükséges oiszt# i&rózís kezeléséhez, Ét (»> CR'R'téhéri«, ahol a CFl'R'fábérj#MpréSS^a.b^ás ÜFFlfepíit szappiémsőiÉI
HUE06822478A 2005-10-28 2006-10-27 Géntranszfer légúti epiteliális õssejtbe, RNS-vírus tüskefehérjével pszeudotipizált lentivírusvektor alkalmazásával HUE028512T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005313971 2005-10-28

Publications (1)

Publication Number Publication Date
HUE028512T2 true HUE028512T2 (hu) 2016-12-28

Family

ID=37967860

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06822478A HUE028512T2 (hu) 2005-10-28 2006-10-27 Géntranszfer légúti epiteliális õssejtbe, RNS-vírus tüskefehérjével pszeudotipizált lentivírusvektor alkalmazásával

Country Status (13)

Country Link
US (4) US20090162320A1 (hu)
EP (2) EP2993235B1 (hu)
JP (3) JPWO2007049752A1 (hu)
KR (1) KR20080068098A (hu)
CN (1) CN101351557A (hu)
CA (1) CA2627485C (hu)
CY (1) CY1117307T1 (hu)
DK (1) DK1950307T3 (hu)
ES (2) ES2561060T3 (hu)
HU (1) HUE028512T2 (hu)
PT (1) PT1950307E (hu)
SI (1) SI1950307T1 (hu)
WO (1) WO2007049752A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
KR101753069B1 (ko) 2015-07-17 2017-07-04 서울대학교병원 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
CN111225682A (zh) * 2017-10-20 2020-06-02 吉尼松公司 合胞素用于将药物和基因靶向递送至肺组织的用途
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
CN111088408A (zh) * 2020-03-20 2020-05-01 广州凯普医药科技有限公司 一种新冠病毒、甲乙流感及呼吸道合胞病毒检测试剂盒
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用
WO2022055894A1 (en) * 2020-09-08 2022-03-17 The Regents Of The University Of California Sars-cov-2 spike glycoprotein for virus generation and pseudotyping
WO2023199049A1 (en) * 2022-04-11 2023-10-19 Ip2Ipo Innovations Limited Combination treatment

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5576201A (en) * 1994-01-14 1996-11-19 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
KR100754091B1 (ko) * 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
JP3992200B2 (ja) 1995-11-01 2007-10-17 株式会社ディナベック研究所 組換え体センダイウイルスを利用した膜融合性リポソーム
CA2236378C (en) * 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
DE69738737D1 (de) 1996-12-16 2008-07-10 Eisai R&D Man Co Ltd Verfahren zur herstellung von retroviralen vektoren für die gentherapie
AU9399498A (en) 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
DE19851282A1 (de) 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
DE19909769A1 (de) * 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
KR20070058607A (ko) 1999-05-18 2007-06-08 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
ES2280254T3 (es) * 1999-11-02 2007-09-16 Dnavec Research Inc. Vector de virus sendai recombinante para introducir genes exogenos en el epitelio de las vias respiratorias.
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
CN1418252A (zh) * 2000-01-19 2003-05-14 株式会社载体研究所 副粘病毒属载体在血管内基因转移中的用途
EP1270016A4 (en) * 2000-03-30 2005-10-19 Dnavec Research Inc VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CN100531802C (zh) * 2000-06-01 2009-08-26 株式会社载体研究所 含有血凝素活性膜蛋白质的假型逆转录病毒载体
JP5014535B2 (ja) 2000-06-15 2012-08-29 田辺三菱製薬株式会社 カニクイザル由来胚性幹細胞
US20030170897A1 (en) * 2000-06-27 2003-09-11 Enyu Imai Virus vector for transferring gene into renal cells
EP1333088A4 (en) * 2000-10-06 2004-11-24 Dnavec Research Inc PARAMYXOVIRUS VECTOR FOR THE INTRODUCTION OF FOREIGN GENES IN SKELETAL MUSCLE
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
WO2002042481A1 (fr) * 2000-11-27 2002-05-30 Dnavec Research Inc. Vecteur paramyxovirus codant pour un gene d'angiogenese et son utilisation
CA2449589A1 (en) 2001-06-08 2002-12-19 Dnavec Research Inc. Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector
GB0202569D0 (en) 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
US7402427B2 (en) 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
WO2003092582A2 (en) * 2002-04-30 2003-11-13 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor
EP1504766A4 (en) 2002-04-30 2006-11-02 Dnavec Research Inc MEDICAMENT OR GENE SUPPORT COMPOSITION WITH HEMAGGLUTININ ACTIVITY
CA2488270A1 (en) 2002-06-03 2003-12-11 Dnavec Research Inc. Paramyxoviral vectors encoding antibodies, and uses thereof
EP1548101A4 (en) 2002-09-04 2006-05-10 Dnavec Research Inc METHOD FOR PRODUCING A VIRAL VECTOR CONTAINING A MEMBRANE PROTEIN BINDING WITH THE NEURAMINIDASE FROM GRAM-POSITIVE BACTERIA TO SIALIC ACID AS AN INTEGRAL PART OF THE ENVELOPE
JPWO2004038029A1 (ja) 2002-10-24 2006-02-23 株式会社ディナベック研究所 Ｔ細胞に遺伝子を導入する方法
US20050113298A1 (en) * 2003-09-15 2005-05-26 The Brigham And Women's Hospital, Inc. Receptor binding peptides derived from the SARS S protein
US20050100890A1 (en) * 2003-10-15 2005-05-12 Davidson Beverly L. Methods for producing and using in vivo pseudotyped retroviruses
WO2005087936A1 (ja) 2004-03-16 2005-09-22 Dnavec Research Inc. 胚性幹細胞に遺伝子を導入する方法

Also Published As

Publication number Publication date
US20160281109A1 (en) 2016-09-29
EP1950307B8 (en) 2016-02-24
EP2993235B1 (en) 2019-02-13
EP1950307A1 (en) 2008-07-30
EP1950307A4 (en) 2010-09-08
US20150174198A1 (en) 2015-06-25
JPWO2007049752A1 (ja) 2009-04-30
CN101351557A (zh) 2009-01-21
KR20080068098A (ko) 2008-07-22
WO2007049752A1 (ja) 2007-05-03
ES2561060T3 (es) 2016-02-24
US20190225986A1 (en) 2019-07-25
CY1117307T1 (el) 2017-04-26
SI1950307T1 (sl) 2016-02-29
DK1950307T3 (en) 2016-02-15
JP5776662B2 (ja) 2015-09-09
CA2627485C (en) 2017-02-21
JP2015126753A (ja) 2015-07-09
EP2993235A1 (en) 2016-03-09
US10017784B2 (en) 2018-07-10
EP1950307B1 (en) 2015-12-23
ES2726176T3 (es) 2019-10-02
PT1950307E (pt) 2016-02-29
JP2013055941A (ja) 2013-03-28
US20090162320A1 (en) 2009-06-25
CA2627485A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
US20190225986A1 (en) Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
CA2413995C (en) Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
JP4861314B2 (ja) 非組み込み型且つ非複製型組換えレンチウイルス、その調製および使用
US8278284B2 (en) Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use SIV-PEDF vectors
CA3177006A1 (en) Compositions and methods for the treatment of cystic fibrosis
JP4971974B2 (ja) Ｐｅｄｆおよびｆｇｆ２を含む眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬
US20060128019A1 (en) Process for producing virus vector containing membrane protein having sialic acid-binding in envelope with the use of gram-positive bacterium origin nueraminidase
JP2005034105A (ja) 原形質膜粒子の放出を促進する方法